The Global X-linked Hypophosphatemia Market is estimated to be valued at USD 40,309.1 Thousand by 2025 and is expected to register a CAGR of 3.6% during the forecast period.
X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by mutations in the phosphate regulating endopeptidase homolog (PHEX), X-Linked gene. XLH is also called as X-linked hypophosphatemic rickets, vitamin D-resistant rickets (VDRR), familial hypophosphatemic rickets, or genetic rickets.
The global X-linked hypophosphatemia market is mainly driven by factors such as rising cases of X-linked hypophosphatemia, increasing awareness about XLH and the severity of the disease, and the proactive initiatives for researching the field of XLH. However, the high cost of the drug and limited availability of treatment options may slow down the growth of the market in the future. On the other hand, a recent drug approval by regulatory authorities such as the US FDA, Health Canada, and the European Medical Agency is likely to offer lucrative opportunities for the growth of the market shortly.
Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6267
Segment Analysis
The X-linked hypophosphatemia (XLH) market by treatment has been segmented into medication and surgical or orthopedic treatment. According to a press release by the US FDA in April 2018, XLH affected approximately 3,000 children and 12,000 adults in the US alone. The increasing number of people suffering from phosphate deficiency is driving the X-Linked Hypophosphatemia market as this raises the demand for the treatment of this disease.
The X-linked hypophosphatemia market has been categorized by the end user into hospitals and clinics and research centers. The hospitals and clinics segment is expected to register a relatively good CAGR during the forecast period from 2019 to 2025. A regular rise in the number of private and government hospitals in developing countries such as India, China, and Indonesia with an increase in the number of diagnosis and treatment procedures for X-linked disorders is expected to support the profitable growth of this segment. According to the survey conducted by the American Hospital Association (AHA), the total number of hospitals in the US are 6,210. Also, the increase in the use of medication, corrective surgery, and dental procedure to cure XLH is supporting the growth of this segment.
Regional Analysis
The XLH market in the Americas is expected to hold a major market share owing to the growing prevalence of XLH in the US and Canada and the presence of a well-established healthcare sector. The rising research funding towards rare diseases such as XLH and the high healthcare expenditure is also expected to fuel the growth of the market during the forecast period. For instance, Genome Canada and the Canadian Institutes for Health Research entered into a partnership to study rare genetic diseases by using Next-Generation Sequencing (NGS) technology.
Followed by America, the European market is expected to be the second-largest X-linked hypophosphatemia market. The rising prevalence rates of XLH, technological advances, well-developed health care sector, and government support for the research and development have fueled the growth of the market.
Asia-Pacific is anticipated to be the fastest-growing market owing to the growing healthcare expenditure and the presence of a large patient pool. Growing investments by market players in the region due to the growing demand for the treatment of rare diseases is expected to contribute to the growth of the market.
Market Players
Market Research Future (MRFR) recognizes Ultragenyx Pharmaceutical (California), Validus Pharmaceuticals LLC (New Jersey), Prospec-Tany Technogene Ltd (Israel), Merck KGaA (Germany), Zeria Pharmaceutical Co., Ltd (Japan), Smith & Nephew (UK), Narang Medical Limited (India), Eli Lilly and Company (Indiana). F. Hoffmann-La Roche (Switzerland) as the key players in the global X-linked hypophosphatemia market.
Key Findings of the Study:
The Global X-linked Hypophosphatemia Market is projected to reach over USD 40,309 thousand by 2025 at a 6% CAGR during the review period of 2019 to 2025.
Asia-Pacific accounted for the largest market share, with Japan being the major contributor to the growth of the market.
The treatment segment is projected to register the highest CAGR of 3.6% during the forecast period as according to the statistics published in 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US.
Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies. Moreover, they are focusing on e-commerce for distribution.
Browse More Details of the Report @ https://www.marketresearchfuture.com/sample_request/6267
About Us:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment